Skip to main content
XRAY
NASDAQ Industrial Applications And Services

Dentsply Sirona Swings to Q2 Profit on Tariff Refunds and Restructuring, Suspends Dividend

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$13.072
Mkt Cap
$2.638B
52W Low
$9.405
52W High
$14.86
52W Position info
39% above low
Off High info
12% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

XRAY sits 39% above its 52-week low of $9.405.

Summary

Dentsply Sirona returned to profitability in Q2 2026 with $0.18 EPS, helped by $44M in tariff refunds and a new restructuring plan, while suspending its dividend to conserve cash.


Key Events · Earnings and Guidance · XRAY

  • Q2 Earnings Swing to Profit

    Net income of $37M ($0.18/share) vs. a loss of $45M (-$0.22) a year ago, beating expectations. Revenue fell 4% to $898M, but gross margin expanded to 54.9% from 52.4%.

  • Tariff Refunds Boost Results

    Received $44M in refunds for previously paid U.S. tariffs under IEEPA, which favorably impacted both gross profit and cash flow in the quarter.

  • New Restructuring Plan Announced

    Board approved a 2026 Plan with $60–65M in expected charges, targeting $120M in annualized cost savings. $57M incurred so far, primarily for severance.

  • Dividend Eliminated

    Board eliminated the quarterly dividend starting Q1 2026 to preserve cash; $1.2B share repurchase authorization remains, with 1.3M shares bought for $12M in Q2.


Analysis · XRAY · Industrial Applications And Services

A sharp turnaround defined Dentsply Sirona's Q2 2026, as net income reached $37 million compared to a $45 million loss a year ago. The swing was fueled by $44 million in tariff refunds and a 250-basis-point gross margin expansion to 54.9%, even as revenue slipped 4%. Management also unveiled a new $60–65 million restructuring plan targeting $120 million in annualized savings, while the board eliminated the quarterly dividend to preserve cash. Although earnings exceeded expectations, the underlying business continues to face pressure from lower volumes and an unfavorable mix, particularly in orthodontics and implants. The restructuring and dividend suspension underscore a focus on cost control and liquidity, but the heavy reliance on one-time tariff refunds and ongoing litigation overhangs temper the positive headline.

At the time of this filing, XRAY was trading at $13.07 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $9.41 to $14.86. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XRAY - Latest Insights

XRAY
Aug 06, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $13.50
Real-time Price: $13.07 info
Change: -$0.428 (-3%) info
Market Cap: $2.638B info
XRAY
Jul 01, 2026, 5:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.09
Real-time Price: $13.07 info
Change: +$1.98 (+18%) info
Market Cap: $2.638B info
XRAY
Jun 11, 2026, 8:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.94
Real-time Price: $13.07 info
Change: +$3.14 (+32%) info
Market Cap: $2.638B info
XRAY
Jun 05, 2026, 3:39 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $9.98
Real-time Price: $13.07 info
Change: +$3.10 (+31%) info
Market Cap: $2.638B info
XRAY
Jun 04, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.86
Real-time Price: $13.07 info
Change: +$3.21 (+33%) info
Market Cap: $2.638B info